Research outputs
2025
High Respiratory Syncytial Virus Burden in Children Under 3 Years of Age Across All Care Levels in England
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.
Munro, A. P. S., Drysdale, S. B., Cathie, K., Flamein, F., Knuf, M., Collins, A. M., . . . HARMONIE Study Group. (2025). 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.. The Lancet. Child & adolescent health, 9(6), 404-412. doi:10.1016/s2352-4642(25)00102-6
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
Harris, V., Holmes, J., Gbinigie-Thompson, O., Rahman, N. M., Richards, D. B., Hayward, G., . . . PANORAMIC Trial Collaborative Group. (2025). Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.. The Lancet. Infectious diseases, 25(1), 68-79. doi:10.1016/s1473-3099(24)00431-6
2023
Surveillance towards preventing paediatric incidence of respiratory syncytial virus attributable respiratory tract infection in primary and secondary/tertiary healthcare settings in Merseyside, Cheshire and Bristol, UK
Fyles, F., Hill, H., Duncan, G., Carter, E., Solorzano, C., Davies, K., . . . Collins, A. M. (2023). Surveillance towards preventing paediatric incidence of respiratory syncytial virus attributable respiratory tract infection in primary and secondary/tertiary healthcare settings in Merseyside, Cheshire and Bristol, UK. BMJ OPEN RESPIRATORY RESEARCH, 10(1). doi:10.1136/bmjresp-2022-001457
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Butler, C. C., Hobbs, F. D. R., Gbinigie, O. A., Rahman, N. M., Hayward, G., Richards, D. B., . . . Little, P. (2023). Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. LANCET, 401(10373), 281-293. doi:10.1016/S0140-6736(22)02597-1